NEFL and myeloid sarcoma: NfL a marker of axonal damage (Norgren et al., 2004; Teunissen and Khalil, 2012; Gaetani et al., 2019; Alirezaei et al., 2020), was analyzed in patients’ CSF and serum samples, and then compared across MS lesional activity subgroups.